Physician profile
Basel Termanini
NPI 1033116157
$7,492.83
in general payments reported to CMS, 2019-2025
30 companies · $651 in 2025
The $651 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,267 · 2020: $507 · 2021: $1,445 · 2022: $1,564 · 2023: $855 · 2024: $1,203 · 2025: $651.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,653 · Education: $56.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,653.25 |
| Education | $56.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,299.31 | 2019-2025 | Xifaxan, Trulance |
| Abbvie INC. | $2,203.30 | 2019-2025 | Linzess, Viberzi, Rinvoq |
| Takeda Pharmaceuticals U.S.A., INC. | $720.32 | 2019-2025 | Entyvio, Eohilia |
| Celgene Corporation | $332.62 | 2021-2024 | Zeposia |
| Janssen Biotech, INC. | $238.62 | 2019-2025 | Stelara, Tremfya |
| E.R. Squibb & Sons, L.L.C. | $225.47 | 2022-2024 | Zeposia |
| Qol Medical, LLC | $184.97 | 2019-2024 | Sucraid |
| Madrigal Pharmaceuticals | $162.47 | 2024-2025 | Rezdiffra, Resmetirom |
| Ironwood Pharmaceuticals, INC | $144.70 | 2019-2023 | Linzess |
| Allergan, INC. | $117.99 | 2019 | |
| Daiichi Sankyo INC. | $102.40 | 2019-2022 | |
| Ardelyx, INC. | $97.11 | 2022-2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $95.59 | 2024-2025 | Voquezna |
| Novo Nordisk INC | $83.17 | 2019-2025 | Wegovy |
| Shionogi INC | $78.71 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $66.95 | 2020-2024 | |
| Genzyme Corporation | $47.66 | 2022-2023 | |
| Alfasigma USA, INC. | $41.45 | 2020-2021 | |
| Aimmune Therapeutics, INC. | $35.43 | 2024-2025 | Zenpep |
| Abbott Laboratories | $24.63 | 2024 | Amplatzer Amulet |
| Celltrion USA INC. | $24.35 | 2024 | Zymfentra |
| Amgen INC. | $24.03 | 2023 | Avsola, Amjevita |
| Evoke Pharma, INC. | $23.44 | 2023 | Gimoti |
| Astrazeneca Pharmaceuticals Lp | $20.27 | 2019 | |
| Redhill Biopharma INC. | $20.21 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $19.38 | 2025 | Dupixent |
| Gilead Sciences, INC. | $17.18 | 2023 | |
| Nestle Healthcare Nutrition INC. | $16.92 | 2022 | |
| Covidien Lp | $12.81 | 2019 | |
| Pfizer INC. | $11.37 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Basel Termanini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.